Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients ; volume:15 ; number:1 ; day:23 ; month:2 ; year:2024 ; pages:1-14 ; date:12.2024
Nature Communications ; 15, Heft 1 (23.2.2024), 1-14, 12.2024
- Urheber
-
Standing, Joseph F.
Buggiotti, Laura
Guerra-Assuncao, Jose Afonso
Woodall, Maximillian
Ellis, Samuel
Agyeman, Akosua A.
Miller, Charles
Okechukwu, Mercy
Kirkpatrick, Emily
Jacobs, Amy I.
Williams, Charlotte A.
Roy, Sunando
Martin-Bernal, Luz M.
Williams, Rachel
Smith, Claire M.
Sanderson, Theo
Ashford, Fiona B.
Emmanuel, Beena
Afzal, Zaheer M.
Shields, Adrian
Richter, Alex G.
Dorward, Jienchi
Gbinigie, Oghenekome
Hecke, Oliver Van
Lown, Mark
Francis, Nick
Jani, Bhautesh
Richards, Duncan B.
Rahman, Najib M.
Yu, Ly-Mee
Thomas, Nicholas P. B.
Hart, Nigel D.
Evans, Philip
Andersson, Monique
Hayward, Gail
Hood, Kerenza
Nguyen-Van-Tam, Jonathan S.
Little, Paul
Hobbs, F. D. Richard
Khoo, Saye
Butler, Christopher
Lowe, David M.
Breuer, Judith
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-024-45641-0
- URN
-
urn:nbn:de:101:1-2404301320452.020725074743
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Standing, Joseph F.
- Buggiotti, Laura
- Guerra-Assuncao, Jose Afonso
- Woodall, Maximillian
- Ellis, Samuel
- Agyeman, Akosua A.
- Miller, Charles
- Okechukwu, Mercy
- Kirkpatrick, Emily
- Jacobs, Amy I.
- Williams, Charlotte A.
- Roy, Sunando
- Martin-Bernal, Luz M.
- Williams, Rachel
- Smith, Claire M.
- Sanderson, Theo
- Ashford, Fiona B.
- Emmanuel, Beena
- Afzal, Zaheer M.
- Shields, Adrian
- Richter, Alex G.
- Dorward, Jienchi
- Gbinigie, Oghenekome
- Hecke, Oliver Van
- Lown, Mark
- Francis, Nick
- Jani, Bhautesh
- Richards, Duncan B.
- Rahman, Najib M.
- Yu, Ly-Mee
- Thomas, Nicholas P. B.
- Hart, Nigel D.
- Evans, Philip
- Andersson, Monique
- Hayward, Gail
- Hood, Kerenza
- Nguyen-Van-Tam, Jonathan S.
- Little, Paul
- Hobbs, F. D. Richard
- Khoo, Saye
- Butler, Christopher
- Lowe, David M.
- Breuer, Judith
- SpringerLink (Online service)
Ähnliche Objekte (12)
Human antibody therapeutics for viral disease
Humanized COVID‐19 decoy antibody effectively blocks viral entry and prevents SARS‐CoV‐2 infection
The prevalence of vascular complications in SARS-CoV-2 infected outpatients
Prolonged viral suppression with anti-HIV-1 antibody therapy
Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients
Development of novel SARS-CoV-2 viral vectors
Viral kinetics of sequential SARS-CoV-2 infections
Neutralizing antibody titres in SARS-CoV-2 infections
The early antibody response to SARS-Cov-2 infection
Viral infections in outpatients with medically attended acute respiratory illness during the 2012–2013 influenza season
SARS-CoV-2 antibody performances: we need better criteria
Antibody cocktail effective against variants of SARS-CoV-2
Human antibody therapeutics for viral disease
Humanized COVID‐19 decoy antibody effectively blocks viral entry and prevents SARS‐CoV‐2 infection
The prevalence of vascular complications in SARS-CoV-2 infected outpatients
Prolonged viral suppression with anti-HIV-1 antibody therapy
Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients
Development of novel SARS-CoV-2 viral vectors
Viral kinetics of sequential SARS-CoV-2 infections
Neutralizing antibody titres in SARS-CoV-2 infections
The early antibody response to SARS-Cov-2 infection
Viral infections in outpatients with medically attended acute respiratory illness during the 2012–2013 influenza season
SARS-CoV-2 antibody performances: we need better criteria
Antibody cocktail effective against variants of SARS-CoV-2
Human antibody therapeutics for viral disease
Humanized COVID‐19 decoy antibody effectively blocks viral entry and prevents SARS‐CoV‐2 infection
The prevalence of vascular complications in SARS-CoV-2 infected outpatients
Prolonged viral suppression with anti-HIV-1 antibody therapy
Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients
Development of novel SARS-CoV-2 viral vectors
Viral kinetics of sequential SARS-CoV-2 infections
Neutralizing antibody titres in SARS-CoV-2 infections
The early antibody response to SARS-Cov-2 infection
Viral infections in outpatients with medically attended acute respiratory illness during the 2012–2013 influenza season
SARS-CoV-2 antibody performances: we need better criteria